Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-17

Phase 1/2 clinical testing of clade C-based HIV-1 candidate vaccines in China

Objective

The number of people living with HIV/AIDS in China is estimated to be >600,000, and projected to rise exponentially. Based on an in depth characterization of the epidemiological situation, three candidate vaccines - an innovative DNA vaccine and two different types of recombinant vaccine viruses - encoding a synthetic , Chinese clad C (CN54) derived Envy and GagPolNef polygene will be tested in a phase 1/2 clinical trial in China. 90 selected HIV negative volunteers will be vaccinated according to different prime/boost regimens and assessed for the safety and immunogenicity of the candidate vaccines. Emphasis will be put on the characterization of (cross-clade) cellular and humoral immune responses towards different regional virus strains. The proposed project also aims to establish the necessary infrastructure for future field trials.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Call for proposal

Data not available

Coordinator

UNIVERSITAET REGENSBURG
EU contribution
No data
Address
11,Frans-Joseph-Strauss-Allee 11
93053 REGENSBURG
Germany

See on map

Total cost
No data

Participants (3)

My booklet 0 0